This company has been marked as potentially delisted and may not be actively trading. AzurRx BioPharma (AZRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock AZRX vs. NNVC, TAOX, IBIO, AEON, OBSV, MTNB, AEZS, NRBO, VAXX, and SPRBShould you be buying AzurRx BioPharma stock or one of its competitors? The main competitors of AzurRx BioPharma include NanoViricides (NNVC), Synaptogenix (TAOX), iBio (IBIO), AEON Biopharma (AEON), ObsEva (OBSV), Matinas Biopharma (MTNB), Aeterna Zentaris (AEZS), NeuroBo Pharmaceuticals (NRBO), Vaxxinity (VAXX), and Spruce Biosciences (SPRB). AzurRx BioPharma vs. Its Competitors NanoViricides Synaptogenix iBio AEON Biopharma ObsEva Matinas Biopharma Aeterna Zentaris NeuroBo Pharmaceuticals Vaxxinity Spruce Biosciences AzurRx BioPharma (NASDAQ:AZRX) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment. Which has better earnings & valuation, AZRX or NNVC? NanoViricides is trading at a lower price-to-earnings ratio than AzurRx BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAzurRx BioPharmaN/AN/A-$32.67M-$11.50-0.05NanoViricidesN/AN/A-$8.29M-$0.70-2.19 Which has more volatility & risk, AZRX or NNVC? AzurRx BioPharma has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, NanoViricides has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Do insiders and institutionals hold more shares of AZRX or NNVC? 6.3% of AzurRx BioPharma shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 7.3% of AzurRx BioPharma shares are held by company insiders. Comparatively, 4.6% of NanoViricides shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is AZRX or NNVC more profitable? NanoViricides' return on equity of -87.90% beat AzurRx BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets AzurRx BioPharmaN/A -482.96% -258.47% NanoViricides N/A -87.90%-78.69% Does the media refer more to AZRX or NNVC? In the previous week, NanoViricides had 1 more articles in the media than AzurRx BioPharma. MarketBeat recorded 1 mentions for NanoViricides and 0 mentions for AzurRx BioPharma. AzurRx BioPharma's average media sentiment score of 0.00 equaled NanoViricides'average media sentiment score. Company Overall Sentiment AzurRx BioPharma Neutral NanoViricides Neutral SummaryNanoViricides beats AzurRx BioPharma on 6 of the 9 factors compared between the two stocks. Get AzurRx BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AZRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AZRX vs. The Competition Export to ExcelMetricAzurRx BioPharmaPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.69M$822.97M$5.70B$9.79BDividend YieldN/A4.84%3.77%4.10%P/E Ratio-0.061.1830.8625.25Price / SalesN/A25.66403.9088.50Price / CashN/A19.5625.2228.45Price / Book-0.806.599.516.00Net Income-$32.67M-$4.67M$3.26B$265.34M AzurRx BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AZRXAzurRx BioPharmaN/A$0.61-0.5%N/A+102.0%$5.69MN/A-0.0612Gap DownNNVCNanoViricides0.3065 of 5 stars$1.51-2.3%N/A-30.9%$24.19MN/A-2.0920News CoverageTAOXSynaptogenixN/A$8.98+7.7%N/AN/A$12.48MN/A-0.894Positive NewsEarnings ReportAnalyst DowngradeGap DownIBIOiBio1.1856 of 5 stars$0.61+5.6%$5.00+726.4%-57.9%$9.99M$375K0.00100News CoverageAEONAEON Biopharma3.4359 of 5 stars$0.71+2.9%$360.00+50,675.7%-99.0%$8.02MN/A3.945OBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050MTNBMatinas Biopharma1.5265 of 5 stars$1.56+5.4%N/AN/A$7.94MN/A-0.3230Short Interest ↓Gap UpAEZSAeterna ZentarisN/A$3.58-0.4%N/A-49.6%$6.42M$2.37M-0.2420NRBONeuroBo PharmaceuticalsN/A$0.64+1.3%N/A-82.5%$5.50MN/A0.0010Gap UpVAXXVaxxinityN/A$0.04-2.3%N/A-57.0%$5.32MN/A-0.0990Gap DownSPRBSpruce Biosciences2.0199 of 5 stars$9.15-8.4%$131.25+1,334.4%-73.4%$5.14M$4.91M-9.7320News CoverageShort Interest ↑Gap Down Related Companies and Tools Related Companies NNVC Alternatives TAOX Alternatives IBIO Alternatives AEON Alternatives OBSV Alternatives MTNB Alternatives AEZS Alternatives NRBO Alternatives VAXX Alternatives SPRB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AZRX) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AzurRx BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AzurRx BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access